Todays Report: Today, Natus Medical Inc. (BABY) Raised to Hold at The Zacks Investment Research

Today, Natus Medical Inc. (BABY) Raised to Hold at The Zacks Investment Research

Natus Medical Inc. (NASDAQ:BABY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “

Several other brokerages have also issued reports on BABY. Benchmark Co. assumed coverage on Natus Medical in a research note on Tuesday, October 4th. They issued a “buy” rating and a $55.00 target price on the stock. Raymond James Financial Inc. upgraded Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target for the company in a research report on Tuesday, September 13th.

Natus Medical (NASDAQ:BABY) traded down 1.41% during trading on Monday, reaching $42.00. The company’s stock had a trading volume of 510,250 shares. The stock has a 50-day moving average price of $40.74 and a 200 day moving average price of $38.82. Natus Medical has a 52-week low of $29.54 and a 52-week high of $51.05. The company has a market cap of $1.36 billion, a PE ratio of 34.15 and a beta of 1.16.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, October 19th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.34 by $0.05. The firm had revenue of $90.90 million for the quarter, compared to analyst estimates of $89.94 million. Natus Medical had a return on equity of 13.53% and a net margin of 10.89%. The business’s revenue was down 3.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.39 earnings per share. On average, analysts expect that Natus Medical will post $1.64 EPS for the current year.

In related news, Director Robert A. Gunst sold 3,250 shares of the business’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $41.92, for a total transaction of $136,240.00. Following the completion of the transaction, the director now directly owns 51,150 shares in the company, valued at $2,144,208. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider James B. Hawkins bought 10,000 shares of Natus Medical stock in a transaction that occurred on Thursday, October 27th. The shares were acquired at an average price of $38.30 per share, with a total value of $383,000.00. Following the completion of the transaction, the insider now owns 469,725 shares of the company’s stock, valued at $17,990,467.50. The disclosure for this purchase can be found here. Corporate insiders own 4.80% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors boosted its position in Natus Medical by 5.5% in the third quarter. BlackRock Fund Advisors now owns 2,373,784 shares of the company’s stock valued at $93,266,000 after buying an additional 123,345 shares during the last quarter. Neuberger Berman Group LLC boosted its position in Natus Medical by 9.9% in the second quarter. Neuberger Berman Group LLC now owns 1,572,351 shares of the company’s stock valued at $59,435,000 after buying an additional 141,770 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Natus Medical by 9.6% in the second quarter. Bank of New York Mellon Corp now owns 1,001,484 shares of the company’s stock valued at $37,858,000 after buying an additional 87,938 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Natus Medical by 1.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 836,870 shares of the company’s stock valued at $32,881,000 after buying an additional 13,806 shares during the last quarter. Finally, State Street Corp boosted its position in Natus Medical by 2.2% in the first quarter. State Street Corp now owns 674,379 shares of the company’s stock valued at $25,914,000 after buying an additional 14,617 shares during the last quarter. Institutional investors and hedge funds own 84.01% of the company’s stock.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Related posts

Leave a Comment